CompanyDrug

Sanofi’s Venglustat Receives FDA Priority Review and Breakthrough Therapy Designation for Type 3 Gaucher Disease

BeOne Medicines and Amgen's Tarlatamab Receives NMPA Conditional Approval for Second-Line ES-SCLC in China
CompanyDrug

BeOne Medicines and Amgen’s Tarlatamab Receives NMPA Conditional Approval for Second-Line ES-SCLC in China

CompanyDrug

Northland Biotech’s Engensis Gene Therapy Receives NMPA Approval for Severe Lower Limb Ischemia Ulcers

AstraZeneca's Fasenra Becomes First Biologic Approved in China for Hypereosinophilic Syndrome
CompanyDrug

AstraZeneca’s Fasenra Becomes First Biologic Approved in China for Hypereosinophilic Syndrome

Shionogi's Symproic (Naldemedine) Receives NMPA Approval for Opioid-Induced Constipation in China
CompanyDrug

Shionogi’s Symproic (Naldemedine) Receives NMPA Approval for Opioid-Induced Constipation in China

CompanyDrug

Sino Biopharmaceutical’s IDH1 Inhibitor TQB3454 Receives NMPA Priority Review for Biliary Tract Cancer

CompanyDeals

Sihuan Pharmaceutical and dProtein Biotechnology Form AI-Powered Medical Aesthetics Joint Venture

CompanyDrug

InnoCare Pharma’s BTK Inhibitor Orelabrutinib Gains NMPA Review Acceptance for Primary Immune Thrombocytopenia Indication

CompanyDeals

Salvectors Receives NMPA Clinical Approval for YB1-X7, World’s First Oncolytic Salmonella Therapy for Advanced Solid Tumors

CompanyDeals

Kexing Pharmaceutical and Sinotherapeutics Partner to Commercialize Tofacitinib Extended-Release Tablets in Kuwait and Mexico

Genrix Bio Licenses BCMA×CD3 Bispecific Velinotamig to Fosun's Yaopharma for Greater China in $268M Deal
CompanyDeals

Genrix Bio Licenses BCMA×CD3 Bispecific Velinotamig to Fosun’s Yaopharma for Greater China in $268M Deal

CompanyDrug

Henlius Biotech Initiates China Dosing in Phase II/III Trial of Novel PD-L1 ADC HLX43 for Squamous NSCLC